<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hum Mol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Hum. Mol. Genet</journal-id>
<journal-id journal-id-type="publisher-id">hmg</journal-id>
<journal-title-group>
<journal-title>Human Molecular Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0964-6906</issn>
<issn pub-type="epub">1460-2083</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28525545</article-id>
<article-id pub-id-type="pmc">5886232</article-id>
<article-id pub-id-type="doi">10.1093/hmg/ddx191</article-id>
<article-id pub-id-type="publisher-id">ddx191</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gene co-expression network analysis for identifying modules and functionally enriched pathways in SCA2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Pflieger</surname>
<given-names>Lance T.</given-names>
</name>
<xref ref-type="aff" rid="ddx191-aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dansithong</surname>
<given-names>Warunee</given-names>
</name>
<xref ref-type="aff" rid="ddx191-aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paul</surname>
<given-names>Sharan</given-names>
</name>
<xref ref-type="aff" rid="ddx191-aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scoles</surname>
<given-names>Daniel R.</given-names>
</name>
<xref ref-type="aff" rid="ddx191-aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Figueroa</surname>
<given-names>Karla P.</given-names>
</name>
<xref ref-type="aff" rid="ddx191-aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meera</surname>
<given-names>Pratap</given-names>
</name>
<xref ref-type="aff" rid="ddx191-aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Otis</surname>
<given-names>Thomas S.</given-names>
</name>
<xref ref-type="aff" rid="ddx191-aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Facelli</surname>
<given-names>Julio C.</given-names>
</name>
<xref ref-type="aff" rid="ddx191-aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pulst</surname>
<given-names>Stefan M.</given-names>
</name>
<xref ref-type="aff" rid="ddx191-aff2">2</xref>
<xref ref-type="corresp" rid="ddx191-cor1"></xref>
<!--<email>stefan.pulst@hsc.utah.edu</email>-->
</contrib>
</contrib-group>
<aff id="ddx191-aff1">
<label>1</label>Department of Biomedical Informatics </aff>
<aff id="ddx191-aff2">
<label>2</label>Department of Neurology, University of Utah, Salt Lake City, UT 84112, USA</aff>
<aff id="ddx191-aff3">
<label>3</label>Department of Neurobiology, University of California Los Angeles, Los Angeles, CA, USA</aff>
<author-notes>
<corresp id="ddx191-cor1"><label>*</label>To whom correspondence should be addressed at: Department of Neurology, Clinical Neurosciences Center, 175 North Medical Drive East, Salt Lake City, UT 84132, USA. Tel: +1 8015856387; Fax: +1 8015814192; Email: <email>stefan.pulst@hsc.utah.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>15</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date iso-8601-date="2017-05-19" pub-type="epub">
<day>19</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>15</day>
<month>8</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>26</volume>
<issue>16</issue>
<fpage>3069</fpage>
<lpage>3080</lpage>
<history>
<date date-type="received">
<day>08</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>22</day>
<month>4</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>5</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<self-uri xlink:href="ddx191.pdf"></self-uri>
<abstract>
<title>Abstract</title>
<p>Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurodegenerative disease caused by CAG repeat expansion in the <italic>ATXN2</italic> gene. The repeat resides in an encoded region of the gene resulting in polyglutamine (polyQ) expansion which has been assumed to result in gain of function, predominantly, for the ATXN2 protein. We evaluated temporal cerebellar expression profiles by RNA sequencing of ATXN2<sup>Q127</sup> mice versus wild-type (WT) littermates. ATXN2<sup>Q127</sup> mice are characterized by a progressive motor phenotype onset, and have progressive cerebellar molecular and neurophysiological (Purkinje cell firing frequency) phenotypes. Our analysis revealed previously uncharacterized early and progressive abnormal patterning of cerebellar gene expression. Weighted Gene Coexpression Network Analysis revealed four gene modules that were significantly correlated with disease status, composed primarily of genes associated with GTPase signaling, calcium signaling and cell death. Of these genes, few overlapped with differentially expressed cerebellar genes that we identified in <italic>Atxn2</italic><sup>−/−</sup> knockout mice versus WT littermates, suggesting that loss-of-function is not a significant component of disease pathology. We conclude that SCA2 is a disease characterized by gain of function for ATXN2.</p>
</abstract>
<funding-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">NINDS</named-content>
<named-content content-type="funder-identifier">10.13039/100000065</named-content>
</funding-source>
<award-id>R21NS081182</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="12"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>